Extended Data Fig. 9: POST-LNPs enable organ-selective delivery to other extrahepatic organs.
(a) Ex vivo organ imaging results showing the fluorescence level of EGFP in placenta, liver, lung, spleen, heart, and kidney of pregnant mice (E16.5). (b) Quantification of absolute radiance of EGFP in the placenta, liver, lung, and spleen under indicated conditions. (c) Stacked bar chart showing the percentage of EGFP radiance change in the placenta, liver, lung, and spleen. (d) Ex vivo organ imaging results showing the fluorescence level of EGFP in bone marrow, liver, lung, spleen, heart, and kidney of mice. (e) Quantification of absolute radiance of EGFP in the bone marrow, liver, lung, and spleen. (f) Stacked bar chart showing the percentage of EGFP radiance change in the bone marrow, liver, lung, and spleen. (g) Ex vivo organ imaging results showing the fluorescence level of EGFP in adipose tissue, liver, lung, spleen, heart, and kidney of mice. (h) Quantification of absolute radiance of EGFP in the adipose tissue, liver, lung, and spleen. (i) Stacked bar chart showing the percentage of EGFP radiance change in the adipose tissue, liver, lung, and spleen. (j) Ex vivo organ imaging results showing the fluorescence level of EGFP in testis, liver, lung, spleen, heart, and kidney of mice. (k) Quantification of absolute radiance of EGFP in the testis, liver, lung, and spleen. (l) Stacked bar chart showing the percentage of EGFP radiance change in the testis, liver, lung, and spleen. One-way analysis of variance (ANOVA) and Dunnett’s multiple comparisonstest were used for statistical analysis. ns: p > 0.05. All data are from n = 3 animals for each condition. All data were plotted as the mean ± s.d. Schematics in a, d, g and j created using BioRender.com.
